ContributorNetwork - Parent company Roche and its American subsidiary, Genentech, dodged a bullet Wednesday from the European medical community for its first-of-its-kind drug Avastin. But the pharmaceutical companies received less positive news in the United States. The cancer treatment drug should not be used against breast cancer in the United States, according to a unanimous vote by the six-member oncology drug review panel of the U.S. Food and Drug Administration, as reported by The Globe and Mail.
You are here:
Health 
Diseases & Conditions Avastin Gains Further Acceptance in Europe; U.S. Still Skeptical
(ContributorNetwork)
Diseases & Conditions Avastin Gains Further Acceptance in Europe; U.S. Still Skeptical
(ContributorNetwork)
